New professional clinical and technical services to accelerate program success
CHICAGO, Nov. 27, 2023 — Experienced cancer risk assessment program experts from Volpara Health Technologies Ltd. (ASX: VHT), a global leader in software for the early detection and prevention of cancer, will be joined by a new technical partner LehYup LLC at the Annual Radiological Society of North America (RSNA) meeting, November 26-29, 2023 (South Hall, Booth #2780).
LehYup LLC, an IT integration and optimization firm, will work alongside Volpara’s professional services and deployment staff by providing advanced Epic® build skills to maximize cancer screening and prevention programs. LehYup staff are available to augment existing Volpara customer IT teams with dedicated staff able to work across Epic modules to reduce incomplete or fractured workflows and improve data management, interdepartmental coordination/communication, and program performance analytics.
“Healthcare networks excel at providing diagnostic testing with advanced technologies. Well trained and dedicated physicians, nurses, and technicians deliver patient care with empathy and compassion. IT teams within healthcare networks deliver amazing results while juggling conflicting priorities,” said Andy Lehman, co-founder, LehYup. “However, when it comes to creating and delivering a comprehensive cancer risk assessment program, healthcare networks typically need assistance to harness the full capabilities of their technology. Our technical services provide dedicated and experienced resources work as an extension of your team with a focus on your cancer screening and prevention initiatives.”
Volpara’s Risk Pathways® is market-leading breast cancer risk assessment software, which is currently used by more than 1,000 providers across the United States to perform more than 3 million risk assessments every year. It helps providers shed the one-size fits all approach to cancer screening by using their existing EHR such as Epic to assess a patient’s a risk of developing multiple forms of cancer—breast, ovarian, endometrial, pancreatic, and colorectal. This comprehensive cancer risk assessment software helps clinicians make better informed decisions for triaging patients to supplemental imaging and/or genetic testing based on their individual risk profile.
“We are committed to removing the roadblocks that are keeping clinicians from providing effective, personalized care. This partnership offers Volpara Risk Pathways customers a unique combination of resources to align the people, processes and technology needed to achieve their clinical, financial, and operational goals,” says Volpara CEO, Teri Thomas. “Volpara’s clinical program expertise and LehYup’s technical skills work together to enhance customer’s speed to market and ability to deliver on the promise of precision medicine, population health, and value-based care.”
Visit Volpara booth #2780 at RSNA for a professional services consult or book an appointment online.
About Volpara Health (ASX: VHT)
Volpara Health makes software to save families from cancer. Healthcare providers use Volpara to better understand cancer risk, empower patients in personal care decisions, and guide recommendations about additional imaging, genetic testing, and other interventions. Our AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality, positioning, compression, and dose. In an industry facing increasing staffing shortages, our software streamlines operations and provides key performance insights that support continuous quality improvement.
Volpara is the preferred partner of leading healthcare institutions around the world. Our software is used in over 2,000 facilities by more than 5,600 technologists, impacting nearly 17 million patients globally. It helps providers conduct more than three million cancer risk assessments each year and can be deployed stand-alone or fully integrated with electronic health record systems, mammography reporting systems, imaging hardware, and genetic laboratories. Volpara holds the most rigorous security certifications and numerous patents and regulatory registrations, including FDA clearance and CE marking. Since listing on the ASX in April 2016, the Company has raised A$132 million. With an office in Seattle, Volpara is based in Wellington, New Zealand.
For more information, visit www.volparahealth.com.
